Antibody-drug maker Raven Biotech goes public with VaxGen merger

See our story about the merger of these two South San Francisco, Calif., biotechs in Monday’s daily briefing at VentureBeat Life Sciences.

Next Story:
Previous Story:

Photo of David P. Hamilton

About the Author,

David Hamilton has been writing for VentureBeat LifeScience since April 2007. He formerly spent 14 years as a reporter for the Wall Street Journal in its San Francisco and Tokyo bureaus. Prior to that, he spent several years as a reporter at Science Magazine and as a reporter/researcher for the New Republic, both in Washington.

blog comments powered by Disqus